CDK9-IN-14
CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC50 of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects[1].
Product Specifications
CAS Number
2650640-17-6
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-in-14.html
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@H]1C[C@H](NC(CO)=O)CCC1)NC2=NC=C(F)C(C3=CC=C(F)C=C3OC)=C2
Molecular Formula
C21H23F2N3O4
Molecular Weight
419.42
References & Citations
[1]WANG Zhenyu. Compound as cyclin-dependent kinase 9 inhibitor and use thereof. WO2021115335A1
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CSB-EP012817HU-01 10 µg
Recombinant Human Epididymal-specific lipocalin-6 (LCN6)
Sign In for Pricing
View Details CSB-EP012817HU-02 50 µg
Recombinant Human Epididymal-specific lipocalin-6 (LCN6)
Sign In for Pricing
View Details CSB-EP012817HU-03 200 µg
Recombinant Human Epididymal-specific lipocalin-6 (LCN6)
Sign In for Pricing
View Details CSB-EP012817HU-04 500 µg
Recombinant Human Epididymal-specific lipocalin-6 (LCN6)
Sign In for Pricing
View Details